Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The term α-synucleinopathies refers to a group of age-related neurological disorders including Parkinson’s disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) that display an abnormal accumulation of alpha-synuclein (α-syn). In contrast to the neuronal α-syn accumulation observed in PD and DLB, MSA is characterized by a widespread oligodendrocytic α-syn accumulation. Transgenic mice expressing human α-syn under the oligodendrocyte-specific myelin basic protein promoter (MBP1-hαsyn tg mice) model many of the behavioral and neuropathological alterations observed in MSA. Fluoxetine, a selective serotonin reuptake inhibitor, has been shown to be protective in toxin-induced models of PD, however its effects in an in vivo transgenic model of α-synucleinopathy remain unclear. In this context, this study examined the effect of fluoxetine in the MBP1-hαsyn tg mice, a model of MSA. Fluoxetine adminstration ameliorated motor deficits in the MBP1-hαsyn tg mice, with a concomitant decrease in neurodegenerative pathology in the basal ganglia, neocortex and hippocampus. Fluoxetine adminstration also increased levels of the neurotrophic factors, GDNF (glial-derived neurotrophic factor) and BDNF (brain-derived neurotrophic factor) in the MBP1-hαsyn tg mice compared to vehicle-treated tg mice. This fluoxetine-induced increase in GDNF and BDNF protein levels was accompanied by activation of the ERK signaling pathway. The effects of fluoxetine adminstration on myelin and serotonin markers were also examined. Collectively these results indicate that fluoxetine may represent a novel therapeutic intervention for MSA and other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
Tu, P., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., & Lee, V. M. ‐. (1998) · Annals of Neurology · doi:10.1002/ana.410440324 · Cited by 686 · cited 1×
“The characteristic oligodendrocytic neuropathological lesions are known as glial cytoplasmic inclusions (GCI) (Arima et al., 1998; Tu et al., 1998; Wakabayashi et al., 1998a, 1998b).”
Backgroundα-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643 · cited 1×
“The characteristic oligodendrocytic neuropathological lesions are known as glial cytoplasmic inclusions (GCI) (Arima et al., 1998; Tu et al., 1998; Wakabayashi et al., 1998a, 1998b).”
BackgroundSpencer, B., Potkar, R., Trejo, M., Rockenstein, E., Patrick, C., Gindi, R., Adame, A., Wyss-Coray, T., & Masliah, E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4390-09.2009 · Cited by 595 · cited 4×
“Cells were allowed to differentiate for four days without additional feeding and were infected with LVα-syn (Spencer et al., 2009) at a multiplicity of infection (MOI) of 30 and left for an additional three days.”
MethodInfluentialSelf-citationNeurodegenerative disease and adult neurogenesis
Winner, B., Kohl, Z., & Gage, F. H. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07613.x · Cited by 405
Wakabayashi, K., Hayashi, S., Kakita, A., Yamada, M., Toyoshima, Y., Yoshimoto, M., & Takahashi, H. (1998) · Acta Neuropathologica · doi:10.1007/s004010050918 · Cited by 347 · cited 1×
“The characteristic oligodendrocytic neuropathological lesions are known as glial cytoplasmic inclusions (GCI) (Arima et al., 1998; Tu et al., 1998; Wakabayashi et al., 1998a, 1998b).”
BackgroundDong, H., Goico, B., Martin, M., Csernansky, C. A., Bertchume, A., & Csernansky, J. G. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.05.040 · Cited by 342 · cited 2×
“…potentiates neurogenesis in human stem cells and hippocampal cells (Chang et al., 2010; Suzuki et al., 2010) and with studies of neurogenesis in the APPsw (Tg2576) mutant mice model of AD (Dong et al., 2004) and the Ts65Dn mouse model of Down syndrome (Bianchi et al., 2010; Clark et al., 2006).”
BackgroundWilkins, A., Majed, H., Layfield, R., Compston, A., & Chandran, S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04967.2003 · Cited by 337 · cited 2×
“Moreover, given that both oligodendrocytes and astrocytes have been reported to express GDNF (Du and Dreyfus, 2002; Schaar et al., 1993; Wilkins et al., 2003), the most parsimonious explanation for the effect of fluoxetine in the MBP1-hαsyn tg mice is that a combinatorial effect on these cell types is responsible for…”
BackgroundHyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes
Kahle, P. J., Neumann, M., Ozmen, L., Müller, V., Jacobsen, H., Spooren, W., Fuss, B., Mallon, B., Macklin, W. B., Fujiwara, H., et al. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf109 · Cited by 314 · cited 1×
“Similarly, tg mice over expressing h-αsyn under the proteolipid protein (PLP) (Kahle et al., 2002) and the 2′, 3′-cyclic nucleotide 3′-phosphodiesterase (CNP) promoter (Yazawa et al., 2005) develop MSA-like pathology.”
Background
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“Fluoxetine ameliorated motor deficits and decreased neurodegenerative pathology in MSA mice.(502) However, a phase II doubleblind, placebo-controlled study on MSA patients found no difference in progression rates (NCT01146548).”
BackgroundLang, A. E., & Espay, A. J. (2018) · Movement Disorders · doi:10.1002/mds.27360 · Cited by 370
Hannan, A. J. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12102 · Cited by 240
Sanacora, G., & Banasr, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.032 · Cited by 239
Neuron-Astrocyte Interactions in Parkinson’s Disease
Miyazaki, I., & Asanuma, M. (2020) · Cells · doi:10.3390/cells9122623 · Cited by 186
Oligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?
Ettle, B., Schlachetzki, J. C. M., & Winkler, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9205-3 · Cited by 160
Self-citationNovel therapeutic approaches in multiple system atrophy
Palma, J.-A., & Kaufmann, H. (2015) · Clinical Autonomic Research · doi:10.1007/s10286-014-0249-7 · Cited by 24
“In this regard, the SSRI fluoxetine has been shown to increase GDNF and BDNF in a transgenic mouse model of a-syn [81], to suppress proinflammatory factors in microglial cell cultures [82], and to promote hippocampal neurogenesis [83].”
BackgroundTranslational therapies for multiple system atrophy: Bottlenecks and future directions
Stefanova, N. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2017.09.016 · Cited by 12
“…age); treatment duration – 1 mo; Increase of GDNF and BDNF, reduction of astrogliosis, reduction of demyelination, reduction of GCIs, neuroprotection, motor improvement (Ubhi et al., 2012) No change in rate of progression (NCT01146548) Difference between preclinical and clinical outcome measures.”
Metadata
- Authors
- Ubhi, K., Inglis, C., Mante, M., Patrick, C., Adame, A., Spencer, B., Rockenstein, E., May, V., Winkler, J., & Masliah, E.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 234
- Issue
- 2
- Pages
- 405-416
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2003940053
- Cited by
- 86
- References
- 23
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.